Literature DB >> 16333420

New modalities in oncology: antisense oligonucleotides.

C Casey Cunningham1.   

Abstract

Entities:  

Year:  2002        PMID： 16333420      PMCID： PMC1276497          DOI： 10.1080/08998280.2002.11927826

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  22 in total

1.  Identification of a major human serum DNA-binding protein as beta 1H of the alternative pathway of complement activation.

Authors:  W D Gardner; P J White; S O Hoch
Journal:  Biochem Biophys Res Commun       Date:  1980-05-14       Impact factor: 3.575

2.  Quantitation of phosphorothioate oligonucleotides in human plasma.

Authors:  J M Leeds; M J Graham; L Truong; L L Cummins
Journal:  Anal Biochem       Date:  1996-03-01       Impact factor: 3.365

Review 3.  The ins and outs of Raf kinases.

Authors:  G Daum; I Eisenmann-Tappe; H W Fries; J Troppmair; U R Rapp
Journal:  Trends Biochem Sci       Date:  1994-11       Impact factor: 13.807

Review 4.  Development of antisense therapeutics. Implications for cancer gene therapy.

Authors:  J F Milligan; R J Jones; B C Froehler; M D Matteucci
Journal:  Ann N Y Acad Sci       Date:  1994-05-31       Impact factor: 5.691

5.  Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein.

Authors:  H M Warenius; L A Seabra; P Maw
Journal:  Int J Cancer       Date:  1996-07-17       Impact factor: 7.396

6.  Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance.

Authors:  C Riva; J P Lavieille; E Reyt; E Brambilla; J Lunardi; C Brambilla
Journal:  Eur J Cancer B Oral Oncol       Date:  1995-11

7.  A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.

Authors:  C C Cunningham; J T Holmlund; R S Geary; T J Kwoh; A Dorr; J F Johnston; B Monia; J Nemunaitis
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

8.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

Authors:  J S Waters; A Webb; D Cunningham; P A Clarke; F Raynaud; F di Stefano; F E Cotter
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

9.  Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue.

Authors:  C O'Brian; V G Vogel; S E Singletary; N E Ward
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

10.  Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.

Authors:  R Marais; Y Light; H F Paterson; C J Marshall
Journal:  EMBO J       Date:  1995-07-03       Impact factor: 11.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.